SMi Systems
Home Our Technology Biomedical Research Diagnosis Team Investors News Publications Careers Contact
HomeOur TechnologyBiomedical Research DiagnosisTeamInvestorsNewsPublicationsCareersContact
SMi Systems
SMi reveals how it has aligned risk processes for its RUO and IVD platforms

SMi describes the differences between the regulatory considerations for research use only (RUO) products and those destined for in vitro diagnostics (IVD) use, and consider how risk management can be simultaneously applied.

 


VIEW PDF
Lucy Eccleston16 October 2024Home News Block, 2024
Facebook0 Twitter 0 Likes
Previous

SMi gains recognition among some of the major biosensor companies

Lucy Eccleston18 October 20242024
Next

Medicines Discovery Catapult presents at the 13th EMMD Conference

Lucy Eccleston14 October 20242024
 

About Us
About SMi
Meet the Team
Careers
Investors
Publications
News
Contact Us

Technology & Sectors
Our Technology
Biomedical Research
Diagnosis

 

Policies & Information
Privacy Policy
Terms of Use
Company Information
Recruitment Privacy Policy

SMi Drug Discovery
Company Registration No.: 11175710
VAT No.: 332498687
Trading as SMi Systems

© 2024 SMi Drug Discovery Limited